OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
510 patients around the world
Available in Argentina, United States
This is an international, multicenter, randomized, open-label, active-controlled, phase 3
clinical trial. The purpose of this trial is to compare the safety and efficacy of
palazestrant (OP-1250) as a single agent to the standard of care endocrine therapy:
either fulvestrant or an aromatase inhibitor (anastrozole, letrozole, or exemestane).
This trial is seeking adult participants with ER+, HER2- advanced or metastatic breast
cancer whose disease has relapsed or progressed on 1 or 2 prior lines of standard-of-care
endocrine therapy for metastatic breast cancer. Prior lines of therapy must include one
line of endocrine therapy in combination with a CDK 4/6 inhibitor. In the dose-selection
part of the trial, approximately 120 participants will be randomized to one of the two
doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter,
approximately 390 participants will be randomized to palazestrant at the selected dose or
to the standard-of-care endocrine therapy.
Olema Pharmaceuticals, Inc.
4Research sites
510Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Adult female or male participants.
ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.
Evaluable disease (measurable disease or bone-only disease).
Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate hematologic, hepatic, and renal functions.
Female participants can be pre-, peri- or postmenopausal.
Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.
Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.
Previously received chemotherapy in the advanced/metastatic setting.
Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy.
History of allergic reactions to study treatment.
Any contraindications to the selected standard-of-care endocrine therapy in the local prescribing information.
Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.
Clinically significant comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment.
Sites
Instituto de Especialidades de la Salud Rosario Clínica del Tórax
Recruiting
España 931, Rosario, Santa Fe
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Dorrego 269, La Rioja
Consultorios Médicos Dr. Doreski
Recruiting
Av. Cabildo, Cdad. Autónoma de Buenos Aires, Argentina
Instituto Médico de la Fundación Estudios Clínicos - Rosario